Rosenqvist E, Harthug S, Frøholm L O, Høiby E A, Bøvre K, Zollinger W D
National Institute of Public Health, Oslo, Norway.
J Clin Microbiol. 1988 Aug;26(8):1543-8. doi: 10.1128/jcm.26.8.1543-1548.1988.
Antibody responses of adult volunteers given a vaccine containing meningococcal capsular polysaccharides (serogroups A, C, Y, and W-135) noncovalently complexed with serotype 2b:P1.2 and 15:P1.16 outer membrane proteins have been studied. Sera were analyzed by enzyme-linked immunosorbent assay methods for immunoglobulin G (IgG), IgM, and IgA antibodies and for bactericidal activities against the homologous strains. The vaccination was performed as a double-blind experiment with 47 volunteers, of whom 23 received the protein-polysaccharide vaccine and 24 received the control preparation containing the polysaccharides only. Ten additional persons volunteered for the protein-polysaccharide vaccine. Before vaccination, carriers of meningococci had significantly higher levels of specific IgG and IgA and also higher bactericidal activities than noncarriers. At 2 weeks postvaccination we found significant IgG and bactericidal antibody responses against both the 2b:P1.2 and 15:P1.16 strains in about 70% of the protein-polysaccharide vaccinees. The immune response induced by disease was compared with that induced by vaccination by analyzing paired sera from 13 survivors of serogroup B serotype 15 meningococcal disease. We found that the mean specific IgG level in acute-phase sera was lower than average in prevaccination sera from the vaccinees but similar to that of healthy noncarriers before vaccination. The convalescent-phase sera showed IgG responses similar to those of the vaccinees, but the IgM response to disease was significantly higher than after vaccination. The immune response to disease caused by serogroup B serotype 15 meningococci was found by enzyme-linked immunosorbent assay analysis to be about the same with outer-membrane antigens from a serotype 2b strain as it was with antigens from a serotype 15 strain.
对成年志愿者接种一种疫苗后的抗体反应进行了研究，该疫苗含有与2b:P1.2和15:P1.16血清型外膜蛋白非共价复合的脑膜炎球菌荚膜多糖（A、C、Y和W-135血清群）。采用酶联免疫吸附测定法分析血清中的免疫球蛋白G（IgG）、IgM和IgA抗体以及针对同源菌株的杀菌活性。疫苗接种作为一项双盲实验，有47名志愿者参与，其中23人接种了蛋白-多糖疫苗，24人仅接种了含多糖的对照制剂。另有10人自愿接种蛋白-多糖疫苗。接种疫苗前，脑膜炎球菌携带者的特异性IgG和IgA水平显著高于非携带者，杀菌活性也更高。接种疫苗后2周，我们发现约70%接种蛋白-多糖疫苗的人对2b:P1.2和15:P1.16菌株均产生了显著的IgG和杀菌抗体反应。通过分析13例B血清群15血清型脑膜炎球菌病幸存者的配对血清，比较了疾病诱导的免疫反应和疫苗接种诱导的免疫反应。我们发现急性期血清中的平均特异性IgG水平低于疫苗接种者接种前血清的平均水平，但与接种疫苗前健康非携带者的水平相似。恢复期血清显示出与疫苗接种者相似的IgG反应，但对疾病的IgM反应显著高于接种疫苗后。通过酶联免疫吸附测定分析发现，B血清群15血清型脑膜炎球菌引起的疾病的免疫反应，与2b血清型菌株的外膜抗原产生的免疫反应和与15血清型菌株的抗原产生的免疫反应大致相同。
